Profile
RENB NVO VRTX REGN MRNA SGEN
Company Name Renovaro Biosciences Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Moderna, Inc. Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $139.36M $582.01B $114.89B $106.45B $50.93B $43.15B
Employees 0.01K 66.02K 5.40K 13.68K 5.60K 3.26K
CEO Hon. Mark R. Dybul M.D. Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. Stephane Bancel Mr. David R. Epstein B.Sc., M.B.A.
Ratings
Trading
RENB NVO VRTX REGN MRNA SGEN
Last Close $0.97 $131.89 $445.21 $982.29 $132.9 $228.74
High 52 $4.87 $199.54 $446.08 $993.35 $137.75 $228.9
Low 52 $0.92 $87.78 $323.57 $692.45 $69.51 $191.51
Price vs. 52 Week High -80.08 % -33.9 % -0.2 % -1.11 % -3.52 % -0.07 %
Price vs. 52 Week Low 5.43 % 50.25 % 37.59 % 41.86 % 91.2 % 19.44 %
Total Return
RENB NVO VRTX REGN MRNA SGEN
1 Month Return -55.09 % 7.48 % 12.92 % 9.53 % 31.05 % 0 %
3 Month Return -57.27 % 6.35 % 5.45 % 3.61 % 50.39 % 0 %
6 Month Return -66.78 % 30.08 % 27.02 % 22.41 % 73.86 % 7.9 %
9 Month Return 0 % -27.98 % 29.11 % 20.91 % 30.78 % 18.68 %
YTD Return -69.4 % 27.49 % 9.42 % 11.84 % 33.63 % 0 %
1 Year Return 0 % -22.66 % 30.29 % 29.41 % 5.28 % 18.33 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
RENB NVO VRTX REGN MRNA SGEN
Dividend Yield Percentage (TTM) - 0.15 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.1 % 8.49 % 6.2 % -3.65 % -3.35 %
Dividend Per Share (TTM) - 0.2 % - - - -
Payout Ratio (TTM) - 47.03 % - - - -
Profitability
RENB NVO VRTX REGN MRNA SGEN
Gross Profit Margin TTM 84.65 % 86.86 % 87.16 % 21.77 % 75.4 %
Return on Assets TTM 29.87 % 16.81 % 11.22 % -35.67 % -20.64 %
Return on Equity TTM 91.82 % 23.61 % 15.15 % -41.83 % -28.06 %
Return on Capital Employed TTM 82.5 % 20.67 % 12.53 % -35.81 % -29.5 %
Net Income Per EBT TTM 79.81 % 84.31 % 95.44 % 124.28 % 101.53 %
EBT Per Ebit TTM 101.7 % 114.62 % 104.74 % 93.44 % 93.47 %
EBIT Per Revenue TTM 45.03 % 40.85 % 29.46 % -99.69 % -34.37 %
Cash Flow To Debt Ratio TTM 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Receivables Turnover TTM 3.87 5.68 2.51 13.32 3.64
Payables Turnover TTM 2.88 3.81 2.51 22.04 2.52
Inventory Turnover TTM 1.12 1.65 0.62 13.67 1.07
Fixed Asset Turnover TTM 248.64 % 685.31 % 310.02 % 186.78 % 471.71 %
Asset Turnover TTM 81.71 % 42.57 % 38.12 % 30.81 % 63.3 %
Operating Cash Flow Per Share TTM 20.95 15.27 43.96 -7.54 -2.87
Free Cash Flow Per Share TTM 11.28 13.48 36.87 -9.61 -3.73
Cash Per Share TTM 208.61 % 3939.31 % 9758.35 % 2235.6 % 657.5 %
Operating Cash Flow Sales Ratio TTM 38.24 % 38.74 % 36.17 % -55.91 % -23.48 %
Free Cash Flow Operating Cash Flow Ratio TTM 53.85 % 88.22 % 83.87 % 127.41 % 129.82 %
Cash Flow Coverage Ratios TTM 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Price To Free Cash Flows Ratio TTM 79.41 33.02 26.78 -13.87 -61.54
Price To Operating Cash Flows Ratio TTM 43.22 29.15 22.35 -17.62 -79.67
Price Cash Flow Ratio TTM 43.22 29.15 22.35 -17.62 -79.67
Income Statement (TTM)
RENB NVO VRTX REGN MRNA SGEN
Revenue $232.26B $9.84B $13.12B $6.75B $1.96B
Gross Profit $196.5B $8.58B $11.3B $2.06B $1.55B
Gross Profit Ratio 84.6% 87.17% 86.16% 30.52% 79.1%
EBITDA $112.94B $3.93B $5.13B $-3.21B $-0.62B
Net Income $83.68B $3.62B $3.95B $-4.71B $-0.61B
EPS Diluted 18.62 13.89 34.77 -12.34 -3.3
Balance Sheet (MRQ)
RENB NVO VRTX REGN MRNA SGEN
Long Term Debt $20.53B $0.72B $2.7B $1.22B $0.04B
Total Liabilities $207.93B $5.15B $7.11B $4.57B $0.87B
Total Equity $106.56B $17.58B $25.97B $13.85B $2.8B
Total Investments $17.5B $3.45B $13.51B $4.68B $1.42B
Total Debt $27.01B $0.81B $2.7B $1.24B $0.04B
Total Assets $314.49B $22.73B $33.08B $18.43B $3.67B
Cash Flow Statement (TTM)
RENB NVO VRTX REGN MRNA SGEN
Net Income $83.68B $3.62B $3.95B $-4.71B $-0.61B
Inventory $-7.42B $-0.32B $-0.27B $0.75B $-0.23B
Dividends Paid $-31.77B $0B $0B $0B $0B
Operating Cash Flow $108.91B $3.54B $4.59B $-3.12B $-0.45B
Capital Expenditure $-38.9B $-0.26B $-0.93B $-0.71B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 1.91
ABCL AbCellera Biologics Inc. 3.64
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.4
ABIO ARCA biopharma, Inc. 3.33
ABOS Acumen Pharmaceuticals, Inc. 3.65
ABSI Absci Corporation 4.615
ABUS Arbutus Biopharma Corporation 2.98
ABVC ABVC BioPharma, Inc. 1.07
ABVX Abivax SA American Depositary Shares 13.64
ACAD ACADIA Pharmaceuticals Inc. 14.79
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.6
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.9478
ACHV Achieve Life Sciences, Inc. 5
ACIU AC Immune SA 3.18
ACLX Arcellx, Inc. 53.62
ACRV Acrivon Therapeutics, Inc. Common Stock 8.89
ACST Acasti Pharma Inc. 2.69
ETFs With Exposure to RENB
Ticker ETF Name Weight Percentage Price
IWC iShares Micro-Cap ETF 0.02265 119.09
GERM ETFMG Treatments, Testing and Advancements ETF 0.5 19.2334
AVSC Avantis U.S. Small Cap Equity ETF 0 52.14
DCOR Dimensional ETF Trust 0.0000109 58.89
Unlock